Quick Take
Tirzepatide is the new heavyweight champion of weight loss peptides. As a dual GLP-1/GIP agonist, it outperforms semaglutide in head-to-head trials. People are losing 20-25% of their body weight. It's what everyone wants when Ozempic isn't enough.
How It Works
Simple Explanation
Tirzepatide activates TWO hunger-related receptors instead of one. It hits both GLP-1 (like Ozempic) and GIP receptors, creating a more powerful appetite-suppressing and metabolic effect.
🔬 Technical Details (Click to expand)
As a dual GIP/GLP-1 receptor agonist, tirzepatide provides synergistic effects on appetite, glucose metabolism, and energy expenditure. GIP receptor activation enhances the GLP-1 effects and may improve tolerability while boosting fat oxidation.
Key Research
Benefits
- 20-25% body weight loss (best in class)
- Superior to semaglutide in comparative trials
- Significant blood sugar improvements
- May be better tolerated than semaglutide for some
- Improvements in blood pressure and lipids
Side Effects
- Nausea — Common (30%)Less than semaglutide for some
- Diarrhea — Common (20%)
- Decreased appetite — CommonThis is kind of the point
- Vomiting — Common (15%)
- Injection site reactions — Occasional
Typical Dosing
Standard Dose
Start at 2.5mg weekly, titrate up to 15mg over several months
Forms Available
- • Subcutaneous injection only
Frequency
Once weekly
⚠️ This is general information only. Always consult a healthcare provider before starting any peptide.
Who It's For
- ✓ People wanting maximum weight loss results
- ✓ Those who plateaued on semaglutide
- ✓ Type 2 diabetics needing glucose control + weight loss
- ✓ People with BMI ≥30 or ≥27 with comorbidities
Who Should Avoid
- ✗ Personal/family history of medullary thyroid cancer
- ✗ History of pancreatitis
- ✗ Pregnant or breastfeeding
- ✗ Severe GI disease
Want the Full Protocol Guide?
Get our comprehensive guide with dosing protocols, stacking strategies, and more.